diABZI STING agonist (Compound 3) (C09-0862-028)

InformationdiABZI STING agonist (Compound 3) diABZI STING agonist (diABZI STING agonist-1, Compound 3) is a potent non-nucleotide STING agonist and has tremendous potential to improve treatment of cancer in humans.TargetsSTINGIn vitroIn human PBMCs, compound 3 induces dose-dependent activation of STING and secretion of IFNβ with an EC50app of 130 nM.In vivoCompound 3 activates secretion of IFNβ, IL-6, TNF, and KC/GROα (also known as CXCL1) in wild-type but not Sting−/− mice. In BALB/c mice administrated 3 mg/kg compound 3 via intravenous injection, compound 3 exhibits systemic exposure with a half-life of 1.4 h and achieves systemic concentrations greater than the half-maximal effective concentration (EC50) for mouse STING (~200 ng/ml). In mice bearing subcutaneous CT-26 tumours, treatment with compound 3 results in significant tumour growth inhibition as measured by tumour volume AUC analysis (P<0.001), and significantly improves survival (P<0.001) with 8 out of 10 mice remaining tumour free at the end of the study on day 43. Specification: 0.98 Molecular Formula: C42H51N13O7 Molecular Weight: 849.95 PubChem CID: 131986624 Isomeric SMILES: CCN1C(=CC(=N1)C)C(=O)NC2=NC3=C(N2C/C=C/CN4C5=C(C=C(C=C5OCCCN6CCOCC6)C(=O)N)N=C4NC(=O)C7=CC(=NN7CC)C)C(=CC(=C3)C(=O)N)OC